Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 189016, 9 pages
http://dx.doi.org/10.1155/2015/189016
Review Article

Current and Potential Applications of Host-Defense Peptides and Proteins in Urology

The Stone Centre at Vancouver General Hospital, Department of Urologic Sciences, University of British Columbia, 2660 Oak Street, Vancouver, BC, Canada V6H 3Z6

Received 10 August 2014; Revised 21 October 2014; Accepted 24 October 2014

Academic Editor: Joel E. López-Meza

Copyright © 2015 Joey Chor Yee Lo and Dirk Lange. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. Gibberd, “Prontosil etc. in puerperal Streptococcus infections,” British Medical Journal, vol. 2, no. 4005, pp. 695–698, 1937. View at Google Scholar
  2. J. Davies and D. Davies, “Origins and evolution of antibiotic resistance,” Microbiology and Molecular Biology Reviews, vol. 74, no. 3, pp. 417–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Spellberg, R. Guidos, D. Gilbert et al., “The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America,” Clinical Infectious Diseases, vol. 46, no. 2, pp. 155–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. R. Dennison, F. Harris, M. Mura, L. H. G. Morton, A. Zvelindovsky, and D. A. Phoenix, “A novel form of bacterial resistance to the action of eukaryotic host defense peptides, the use of a lipid receptor,” Biochemistry, vol. 52, no. 35, pp. 6021–6029, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. D. A. Tadesse, S. Zhao, E. Tong et al., “Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950–2002,” Emerging Infectious Diseases, vol. 18, no. 5, pp. 741–749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. I. M. Cullen, R. P. Manecksha, E. McCullagh et al., “The changing pattern of antimicrobial resistance within 42 033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999–2009,” BJU International, vol. 109, no. 8, pp. 1198–1206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Minardi, R. Ghiselli, O. Cirioni et al., “The antimicrobial peptide Tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model,” Peptides, vol. 28, no. 12, pp. 2293–2298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. E. Hancock, “Cationic peptides: effectors in innate immunity and novel antimicrobials,” The Lancet Infectious Diseases, vol. 1, no. 3, pp. 156–164, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. C. D. Fjell, J. A. Hiss, R. E. W. Hancock, and G. Schneider, “Designing antimicrobial peptides: form follows function,” Nature Reviews Drug Discovery, vol. 11, no. 1, pp. 37–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. L. Mangoni, “Host-defense peptides: from biology to therapeutic strategies,” Cellular and Molecular Life Sciences, vol. 68, no. 13, pp. 2157–2159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Baltzer and M. H. Brown, “Antimicrobial peptides—promising alternatives to conventional antibiotics,” Journal of Molecular Microbiology and Biotechnology, vol. 20, no. 4, pp. 228–235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. R. E. Hancock and H.-G. Sahl, “Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies,” Nature Biotechnology, vol. 24, no. 12, pp. 1551–1557, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Williams, H. Y. Sroussi, K. Leung, and P. T. Marucha, “Antimicrobial decapeptide KSL-W enhances neutrophil chemotaxis and function,” Peptides, vol. 33, no. 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. S. Ali, C. L. Townes, J. Hall, and R. S. Pickard, “Maintaining a sterile urinary tract: the role of antimicrobial peptides,” The Journal of Urology, vol. 182, no. 1, pp. 21–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. K. Marr, W. J. Gooderham, and R. E. Hancock, “Antibacterial peptides for therapeutic use: obstacles and realistic outlook,” Current Opinion in Pharmacology, vol. 6, no. 5, pp. 468–472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. K. A. Brogden, “Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?” Nature Reviews Microbiology, vol. 3, no. 3, pp. 238–250, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Haversen, I. Engberg, L. Baltzer, G. Dolphin, L. A. Hanson, and I. Mattsby-Baltzer, “Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice,” Infection and Immunity, vol. 68, no. 10, pp. 5816–5823, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Gao, D. Lange, K. Hilpert et al., “The biocompatibility and biofilm resistance of implant coatings based on hydrophilic polymer brushes conjugated with antimicrobial peptides,” Biomaterials, vol. 32, no. 16, pp. 3899–3909, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Li, P. Li, R. Saravanan et al., “Antimicrobial functionalization of silicone surfaces with engineered short peptides having broad spectrum antimicrobial and salt-resistant properties,” Acta Biomaterialia, vol. 10, no. 1, pp. 258–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Lehmann, M. Retz, S. S. Sidhu et al., “Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines,” European Urology, vol. 50, no. 1, pp. 141–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Baker, W. L. Maloy, M. Zasloff, and L. S. Jacob, “Anticancer efficacy of Magainin2 and analogue peptides,” Cancer Research, vol. 53, no. 13, pp. 3052–3057, 1993. View at Google Scholar · View at Scopus
  22. P. W. Soballe, W. L. Maloy, M. L. Myrga, L. S. Jacob, and M. Herlyn, “Experimental local therapy of human-melanoma with lytic magainin peptides,” International Journal of Cancer, vol. 60, no. 2, pp. 280–284, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Suttmann, M. Retz, F. Paulsen et al., “Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells,” BMC Urology, vol. 8, article 5, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Huang, J. Seo, S. B. Willingham et al., “Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity,” PLoS ONE, vol. 9, no. 2, Article ID e90397, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. C. D. Donald, C. Q. Sun, S. D. Lim et al., “Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas,” Laboratory Investigation, vol. 83, no. 4, pp. 501–505, 2003. View at Google Scholar
  26. C. Q. Sun, R. Arnold, C. Fernandez-Golarz et al., “Human β-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma,” Cancer Research, vol. 66, no. 17, pp. 8542–8549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. R. S. Bullard, W. Gibson, S. K. Bose et al., “Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer,” Molecular Immunology, vol. 45, no. 3, pp. 839–848, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Farmanesh, J. Chung, D. Chandra, R. D. Sosa, P. Karande, and J. D. Rimer, “High-throughput platform for design and screening of peptides as inhibitors of calcium oxalate monohydrate crystallization,” Journal of Crystal Growth, vol. 373, pp. 13–19, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Chromek, Z. Slamová, P. Bergman et al., “The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection,” Nature Medicine, vol. 12, no. 6, pp. 636–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. D. Spencer, A. L. Schwaderer, H. Wang et al., “Ribonuclease 7, an antimicrobial peptide upregulated during infection, contributes to microbial defense of the human urinary tract,” Kidney International, vol. 83, no. 4, pp. 615–625, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Weichhart, M. Haidinger, W. H. Hörl, and M. D. Säemann, “Current concepts of molecular defence mechanisms operative during urinary tract infection,” European Journal of Clinical Investigation, vol. 38, supplement 2, pp. 29–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. V. Valore, C. H. Park, A. J. Quayle, K. R. Wiles, P. B. McCray Jr., and T. Ganz, “Human β-defensin-1: an antimicrobial peptide of urogenital tissues,” The Journal of Clinical Investigation, vol. 101, no. 8, pp. 1633–1642, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Pan, G. A. Sonn, M. L. Y. Sin et al., “Electrochemical immunosensor detection of urinary lactoferrin in clinical samples for urinary tract infection diagnosis,” Biosensors and Bioelectronics, vol. 26, no. 2, pp. 649–654, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Legrand, E. Elass, A. Pierce, and J. Mazurier, “Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties,” BioMetals, vol. 17, no. 3, pp. 225–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Rivas-Santiago, C. J. Serrano, and J. A. Enciso-Moreno, “Susceptibility to infectious diseases based on antimicrobial peptide production,” Infection and Immunity, vol. 77, no. 11, pp. 4690–4695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. K. L. Nielsen, P. Dynesen, P. Larsen, L. Jakobsen, P. S. Andersen, and N. Frimodt-Møller, “Role of urinary cathelicidin LL-37 and human β-defensin 1 in uncomplicated escherichia coli urinary tract infections,” Infection and Immunity, vol. 82, no. 4, pp. 1572–1578, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Hertting, Å. Holm, P. Lüthje et al., “Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder,” PLoS ONE, vol. 5, no. 12, Article ID e15580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C. E. Rivas-Santiago, B. Rivas-Santiago, D. A. León, J. Castañeda-Delgado, and R. Hernández Pando, “Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis,” Clinical and Experimental Immunology, vol. 164, no. 1, pp. 80–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Schwab, V. Reynders, Y. Shastri, S. Loitsch, J. Stein, and O. Schröder, “Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells,” Molecular immunology, vol. 44, no. 8, pp. 2107–2114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Schauber, R. A. Dorschner, A. B. Coda et al., “Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism,” The Journal of Clinical Investigation, vol. 117, no. 3, pp. 803–811, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Lüthje, A. Lindén Hirschberg, and A. Brauner, “Estrogenic action on innate defense mechanisms in the urinary tract,” Maturitas, vol. 77, no. 1, pp. 32–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Becknell, J. D. Spencer, A. R. Carpenter et al., “Expression and antimicrobial function of beta-defensin 1 in the lower urinary tract,” PLoS ONE, vol. 8, no. 10, Article ID e77714, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Lo, D. Lange, and B. Chew, “Ureteral stents and foley catheters-associated urinary tract infections: the role of coatings and materials in infection prevention,” Antibiotics, vol. 3, no. 1, pp. 87–97, 2014. View at Google Scholar
  44. P. J. Nowatzki, R. R. Koepsel, P. Stoodley et al., “Salicylic acid-releasing polyurethane acrylate polymers as anti-biofilm urological catheter coatings,” Acta Biomaterialia, vol. 8, no. 5, pp. 1869–1880, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. F. L. Brancatisano, G. Maisetta, M. Di Luca et al., “Inhibitory effect of the human liver-derived antimicrobial peptide hepcidin 20 on biofilms of polysaccharide intercellular adhesin (PIA)-positive and PIA-negative strains of Staphylococcus epidermidis,” Biofouling, vol. 30, no. 4, pp. 435–446, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. J. W. Costerton, P. S. Stewart, and E. P. Greenberg, “Bacterial biofilms: a common cause of persistent infections,” Science, vol. 284, no. 5418, pp. 1318–1322, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Høiby, T. Bjarnsholt, M. Givskov, S. Molin, and O. Ciofu, “Antibiotic resistance of bacterial biofilms,” International Journal of Antimicrobial Agents, vol. 35, no. 4, pp. 322–332, 2010. View at Publisher · View at Google Scholar
  48. N. Hoiby, O. Ciofu, H. K. Johansen et al., “The clinical impact of bacterial biofilms,” International Journal of Oral Science, vol. 3, no. 2, pp. 55–65, 2011. View at Google Scholar
  49. “Cancer research UK,” Nature Cell Biology, vol. 4, no. 3, article E45, 2002. View at Publisher · View at Google Scholar
  50. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. W. Oosterlinck, B. Lobel, G. Jakse, P.-U. Malmström, M. Stöckle, and C. Sternberg, “Guidelines on bladder cancer,” European Urology, vol. 41, no. 2, pp. 105–112, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Stenzl, N. C. Cowan, M. de Santis et al., “Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines,” European Urology, vol. 59, no. 6, pp. 1009–1018, 2011. View at Google Scholar
  53. A. Böhle, D. Jocham, and P. R. Bock, “Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity,” The Journal of Urology, vol. 169, no. 1, pp. 90–95, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Brausi, J. Oddens, R. Sylvester et al., “Side effects of bacillus calmette-guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG,” European Urology, vol. 65, no. 1, pp. 69–76, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. A. P. M. van der Meijden, M. Brausi, V. Zambon et al., “Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk TA, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial,” The Journal of Urology, vol. 166, no. 2, pp. 476–481, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. J. I. Fletcher, M. Haber, M. J. Henderson, and M. D. Norris, “ABC transporters in cancer: more than just drug efflux pumps,” Nature Reviews Cancer, vol. 10, no. 2, pp. 147–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. R. A. Cruciani, J. L. Barker, M. Zasloff, H.-C. Chen, and O. Colamonici, “Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3792–3796, 1991. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Ohsaki, A. F. Gazdar, H.-C. Chen, and B. E. Johnson, “Antitumor activity of magainin analogues against human lung cancer cell lines,” Cancer Research, vol. 52, no. 13, pp. 3534–3538, 1992. View at Google Scholar · View at Scopus
  59. W. L. Maloy and U. P. Kari, “Structure-activity studies on magainins and other host defense peptides,” Biopolymers, vol. 37, no. 2, pp. 105–122, 1995. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Bessalle, A. Kapitkovsky, A. Gorea, I. Shalit, and M. Fridkin, “All-D-magainin: chirality, antimicrobial activity and proteolytic resistance,” FEBS Letters, vol. 274, no. 1-2, pp. 151–155, 1990. View at Google Scholar · View at Scopus
  61. R. J. Boohaker, M. W. Lee, P. Vishnubhotla, J. M. Perez, and A. R. Khaled, “The use of therapeutic peptides to target and to kill cancer cells,” Current Medicinal Chemistry, vol. 19, no. 22, pp. 3794–3804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Winder, W. H. Günzburg, V. Erfle, and B. Salmons, “Expression of antimicrobial peptides has an antitumour effect in human cells,” Biochemical and Biophysical Research Communications, vol. 242, no. 3, pp. 608–612, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. H. G. Boman, “Antibacterial peptides: basic facts and emerging concepts,” Journal of Internal Medicine, vol. 254, no. 3, pp. 197–215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. N. P. Chongsiriwatana, J. A. Patch, A. M. Czyzewski et al., “Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 8, pp. 2794–2799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Droin, J.-B. Hendra, P. Ducoroy, and E. Solary, “Human defensins as cancer biomarkers and antitumour molecules,” Journal of Proteomics, vol. 72, no. 6, pp. 918–927, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Tang, P. Mettler, K. Mcfann, and M. Chonchol, “The association of prevalent kidney stone disease with mortality in US adults: the national health and nutrition examination survey III, 1988–1994,” American Journal of Nephrology, vol. 37, no. 5, pp. 501–506, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. K. K. Stamatelou, M. E. Francis, C. A. Jones, L. M. Nyberg Jr., and G. C. Curhan, “Time trends in reported prevalence of kidney stones in the United States: 1976–1994,” Kidney International, vol. 63, no. 5, pp. 1817–1823, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. A. D. Rule, A. E. Krambeck, and J. C. Lieske, “Chronic kidney disease in kidney stone formers,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 8, pp. 2069–2075, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. F. L. Coe and J. R. Asplin, “Stopping the stones,” Science, vol. 330, no. 6002, pp. 325–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. B. P. H. Chan, K. Vincent, G. A. Lajoie, H. A. Goldberg, B. Grohe, and G. K. Hunter, “On the catalysis of calcium oxalate dihydrate formation by osteopontin peptides,” Colloids and Surfaces B: Biointerfaces, vol. 96, pp. 22–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. J. C. Lieske and F. G. Toback, “Renal cell-urinary crystal interactions,” Current Opinion in Nephrology and Hypertension, vol. 9, no. 4, pp. 349–355, 2000. View at Google Scholar
  72. N. S. Mandel and G. S. Mandel, “Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition,” Journal of Urology, vol. 142, no. 6, pp. 1516–1521, 1989. View at Google Scholar · View at Scopus
  73. B. B. Tomazic and G. H. Nancollas, “The kinetics of dissolution of calcium oxalate hydrates. II. The dihydrate,” Investigative Urology, vol. 18, no. 2, pp. 97–101, 1980. View at Google Scholar · View at Scopus
  74. D. T. Denhardt, M. Noda, A. W. O'Regan, D. Pavlin, and J. S. Berman, “Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival,” The Journal of Clinical Investigation, vol. 107, no. 9, pp. 1055–1061, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Uede, Y. Katagiri, J. Iizuka, and M. Murakami, “Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein?” Microbiology and Immunology, vol. 41, no. 9, pp. 641–648, 1997. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Singh, D. Deonarine, V. Shanmugam et al., “Calcium-binding properties of osteopontin derived from non-osteogenic sources,” Journal of Biochemistry, vol. 114, no. 5, pp. 702–707, 1993. View at Google Scholar · View at Scopus
  77. T. Jung, X. Sheng, C. K. Choi, W.-S. Kim, J. A. Wesson, and M. D. Ward, “Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy,” Langmuir, vol. 20, no. 20, pp. 8587–8596, 2004. View at Publisher · View at Google Scholar · View at Scopus